Core Technology

NEWGLAB Core Technology

One of the missions of NewG Lab Pharma
(NGLP) will be to develop novel anticancer
therapeutics that extend the life of cancer patients
without compromising the quality of life.

Real World Case Study

Real World Case 1 – 16 Y/O Male
A Translational Study "Case Report" on the Small Molecule "Energy Blocker" 3-Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside(2012)
The first patient to be treated with Dr. Ko's 3BP compound.

Treated at Frankfurt University in 2009

16yr old patient with progressive fibrolamellar hepatocellular carcinoma, 3 month of prognosis

The patient was given 9 doses of KAT (200 mg) over a period of 6 months

After treatment, the patient loses cancer and the tissue regenerates from 5% to 30%

1.5years after CR, the patient dies of pneumonia due to excessive antibiotic therapy
that destroyed liver function. No cancer was found as a result of CT scan by postmortem examination.

- Left images taken before treatment, right images taken after 9th treatment.

- Tumors throughout liver (L) are necrotic, encapsulated, and showing fibrosis.

- Lymph nodes that were enlarged (green star) have returned to stable size and shape.

- Spleen size (S) that was enlarged has drastically reduced.

Real World Case 2 – 70 Y/O Male w/ Melanoma
In 2017, 70 y/o male had biopsy taken of forehead growth.

While waiting for the results, the patient starts applying wet gauze to the wound with KAT

A biopsy revealed the melanoma and scheduled surgery. The melanoma disappears
as wound area heals

Observation of patients for one year without proof of recurrence

Real World Case 3 – 100 Y/O Male

He was diagnosed with bladder cancer in February 2018, and biopsy showed high levels of
aggressive urethra epithelial cell carcinoma

PET tests before treatment showed three cancers in the bladder and one in the lung.

After bladder KAT therapy wash, the bladder was cleaned. Also found three cancers in the lung
which were diagnosed in PET scan.
(Note: It is common for KAT to discover other tumors that have not yet been identified in PET imaging.)

After IV and in-mouth KAT treatment, bladder wash was also performed, and the third PET
scan showed only one cancer in the lung area and the mass was smaller.

Now he is doing well and using ketone-producing diets with supplements.

April 2018 : A urologist eventually removed a tumor that was found only to the extent that surgery was possible.
Biopsy revealed advanced aggressive epithelial cancer.

May 2018 : Patient began a KAT bladder washing treatment applied through a catheter.

June 2018 (A) : PET scan showed no lesions in bladder but 3 lesions in lung.

July 2018 : IV and oral KAT therapy were added. The bladder wash continued on most alternate days,
without IV treatment.

Sep. 2018 (B) : PET scan showed small spots in the lungs and are one of the notable, not two or three rounds in June.
There was no cancer in the bladder.

Real World Case 4 – Mid-50s Y/O Female

A patient suffers from Stage IV neuroendocrine cancer has been receiving intermittent
KAT treatment for the past decade.

Genetic reasons have caused her tumor to reappear several times, but the KAT was able to control
it effectively without side effects.

The patient still lives a normal life. (Bottom Right, 20th Oct. 2018)

Candidates of Initial Indication